肿瘤细胞治疗研究
英文原题：Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting.
Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting.
目前，多种现货型嵌合抗原受体（CAR）-T 细胞产品正在被研究用于治疗复发或难治性（R/R）B 细胞肿瘤。
目前，多种现货型嵌合抗原受体（CAR）T 细胞产品正在研究用于治疗复发或难治性（R/R）B 细胞肿瘤。与自体 CAR-T 相比，现货型通用 CAR-T 疗法具有多项潜在优势，例如患者可立即获得治疗、工业化生产保证质量稳定，以及可追加输注靶向不同抗原的 CAR-T 细胞。然而，移植物抗宿主病和宿主免疫系统清除 CAR-T 细胞等关键挑战仍需广泛研究。最常见的技术路线是通过基因编辑改造健康供者 T 细胞，并调整不同类型的 T 细胞。本文总结 2023 年美国血液学会年会（ASH 2023）公布的现货型 CAR-T 治疗 R/R B 细胞恶性肿瘤临床前及临床研究最新数据。
Currently, many off-the-shelf chimeric antigen receptor (CAR)-T cell products are under investigation for the treatment of relapsed or refractory (R/R) B-cell neoplasms. Compared with autologous CAR-T cell therapy, off-the-shelf universal CAR-T cell therapies have many potential benefits, such as immediate accessibility for patients, stable quality due to industrialized manufacturing and additional infusions of CAR-T cells with different targets. However, critical challenges, including graft-versus-host disease and CAR-T cell elimination by the host immune system, still require extensive research. The most common technological approaches involve modifying healthy donor T cells via gene editing technology and altering different types of T cells. This article summarizes some of the latest data from preclinical and clinical studies of off-the-shelf CAR-T cell therapies in the treatment of R/R B-cell malignancies from the 2023 ASH Annual Meeting (ASH 2023).
MEMBER ACCOUNT
登录成功会直接打开下一页。
